Tapentadol

An opioid analgesic, MU OPIOID RECEPTOR agonist, and noradrenaline reuptake inhibitor that is used in the treatment of moderate to severe pain, and of pain associated with DIABETIC NEUROPATHIES.

Also Known As:

Networked: 419 relevant articles (120 outcomes, 159 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Etropolski, Mila: 18 articles (01/2019 - 06/2010)
2.	Rauschkolb, Christine: 14 articles (11/2015 - 05/2009)
3.	Okamoto, Akiko: 14 articles (08/2013 - 11/2008)
4.	Tzschentke, Thomas M: 13 articles (01/2020 - 10/2007)
5.	Lange, Bernd: 12 articles (12/2018 - 01/2010)
6.	Steigerwald, Ilona: 12 articles (01/2016 - 01/2012)
7.	Upmalis, David: 12 articles (08/2013 - 11/2008)
8.	Coluzzi, Flaminia: 11 articles (10/2021 - 06/2014)
9.	Elling, Christian: 10 articles (03/2022 - 07/2015)
10.	Sohns, Melanie: 10 articles (01/2021 - 01/2018)

Related Diseases

1.	Pain (Aches) 11/01/2019 - "Tapentadol PR, adequately titrated according to patients' need, are safe and effective to control pain in most elderly patients." 03/01/2020 - "Results: Tapentadol PR treatment (up to 3 months) significantly reduced pain intensity and pain-related restrictions on daily functioning and significantly improved physical and mental quality of life in both patient groups. " 01/01/2017 - "Compared with tapentadol IR 50 mg, tapentadol IR 75 mg demonstrated significant improvement in moderate to severe pain relief based on both SPID 48 and TOTPAR 48 scores (all P  <   0.05). " 06/01/2015 - "This was accompanied by a significant decrease in pain-related impairments of daily activities and an improvement in quality of life with an overall good tolerability of tapentadol PR. " 01/01/2015 - "Good pain control with tapentadol PR was accompanied by markedly reduced pain-related mental and physical burden and quality of life improved. "
2.	Chronic Pain 11/01/2015 - "Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial." 11/01/2015 - "Tapentadol extended release (ER) has demonstrated efficacy and safety for the management of moderate to severe, chronic pain in adults. " 01/01/2013 - "Efficacy of tapentadol ER for managing moderate to severe chronic pain." 01/01/2022 - "Routine clinical practice indirectly confirmed the more favourable gastrointestinal tolerability of tapentadol PR in the treatment of chronic pain which had previously been demonstrated in clinical trials and non-interventional studies. " 11/01/2019 - "The aim of the study was to assess the efficacy and tolerability of tapentadol prolonged release (PR), administered to patients aged ≥ 70 years with chronic pain. "
3.	Low Back Pain (Lumbago) 01/01/2011 - "Tapentadol in the management of chronic low back pain: a novel approach to a complex condition?" 08/01/2010 - "Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study." 11/01/2019 - "Efficacy of tapentadol prolonged release for pre- and post-operative low back pain: a prospective observational study." 08/01/2018 - "This study investigates the effectiveness, safety and tolerability of the prolonged release oral formulation of tapentadol (tapentadol PR) in 27 patients affected by refractory chronic low back pain during a long-term follow-up (up to 51 months). " 06/01/2015 - "Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study."
4.	Neuralgia (Stump Neuralgia) 12/01/2018 - "Improved therapeutic potential of tapentadol employing cationic exchange resins as carriers in neuropathic pain: evidence from pharmacokinetic and pharmacodynamics study." 02/01/2011 - "[Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. " 05/01/2011 - "This dual mode of action may make tapentadol particularly useful in the treatment of neuropathic pain. " 01/01/2013 - "Differences in the design and duration of these phase 3 studies may limit comparisons of the efficacy results; nevertheless, this summary of efficacy results demonstrates the broad efficacy of tapentadol ER for different types of nociceptive and neuropathic pain. " 01/01/2013 - "To review the efficacy of tapentadol extended release (ER) for the management of moderate to severe chronic nociceptive and neuropathic pain. "
5.	Cancer Pain 01/01/2019 - "According to available evidence, tapentadol prolonged release was well tolerated and effective in cancer pain patients. " 01/01/2019 - "Previous studies have shown the efficacy of tapentadol (TP) for chronic cancer pain. " 01/01/2023 - "This review describes all randomized and recent nonrandomized studies of tapentadol in adults with cancer pain. " 01/01/2020 - "In this study, we conducted a pharmacokinetic analysis of tapentadol (TP) in Japanese patients with cancer pain and identified covariates influencing pharmacokinetic parameters. " 11/01/2017 - "All these studies concluded that tapentadol is seemingly a well-tolerated and efficacious agent for moderate-severe cancer pain, with few typically mild adverse reactions. "

Related Drugs and Biologics

1.	Oxycodone (Oxycontin)
2.	Opioid Analgesics (Opioids)
3.	Analgesics (Analgesic Drugs)
4.	Tramadol (K315)
5.	Morphine (MS Contin)
6.	NAD (NADH)
7.	Norepinephrine (Noradrenaline)
8.	Opioid Receptors (Opioid Receptor)
9.	Naloxone (Narcan)
10.	Pregabalin (Lyrica)

Related Therapies and Procedures

1.	Therapeutics
2.	Analgesia
3.	Drug Therapy (Chemotherapy)
4.	Replacement Arthroplasty
5.	Hysterectomy